Modified treat-and-extend regimen effective for macular oedema due to CRVO

A modified treat-and-extend (mTAE) regimen utilizing aflibercept has shown significant promise as a personalized therapy for managing macular oedema (MO) resulting from central retinal vein occlusion (CRVO), according to a study.

The study enrolled a total of 50 patients with MO due to CRVO who were treated with intravitreal aflibercept injections on an mTAE regimen for 24 months. At baseline, patients exhibited a mean best-corrected visual acuity (BCVA) of 0.50 (logMAR) and a central subfield thickness (CST) of 557 µm, as measured by optical coherence tomography (OCT). The study’s primary outcome measures, BCVA and CST, were evaluated at both the 12 and 24-month marks.

There were substantial and statistically significant improvements in both BCVA and CST at the 12-month milestone, with BCVA improving to 0.19 (logMAR) and CST decreasing to 275 µm. These improvements were statistically significant (P < 0.0001, paired t-test).

The positive trend continued at the 24-month follow-up, with BCVA demonstrating a mean of 0.26 (logMAR) and CST continuing its decrease to 255 µm. These outcomes were statistically significant (P = 0.0004 for BCVA and P < 0.0001 for CST, paired t-test).

Throughout the study’s duration, patients received an average of 6.2 intravitreal aflibercept injections, with clinic visits averaging 10.3 over the 24 months.

Reference
Arai Y, Takahashi H, Inoda S, et al. Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study. J Clin Med. 2023;12(15):5089. doi: 10.3390/jcm12155089. PMID: 37568491; PMCID: PMC10419814.